From the San Francisco Business Times:
Gilead Sciences Inc. said Atripla -- the three-in-one HIV treatment developed in concert with Bristol-Myers Squibb Co. -- was approved by Canadian drug regulators for use by adults with HIV-1 infection.
Atripla combines Gilead's (NASDAQ: GILD) HIV drug Truvada -- itself a combination of the Foster City-based company's Viread and Emtriva -- with Bristol-Myers Squibb's (NYSE: BMY) Sustiva. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment